Plain-English translation of NCT07321626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called to see if it helps patients recover their platelet cells more quickly after a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Platelets are blood cells that help stop bleeding, and they often take a long time to come back after transplant. The medication is given as a weekly injection under the skin, and researchers want to know if the treatment can speed up recovery and reduce bleeding problems.
After a stem cell transplant, patients often experience dangerously low platelet counts for weeks, which increases the risk of serious bleeding and requires frequent blood transfusions. This study is exploring whether this new treatment could help platelets recover faster, reduce the need for transfusions, and improve overall recovery after transplant.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the study, you will be randomly assigned to either receive the new medication or standard care. If assigned to the treatment group, you will receive the medication as an injection under the skin once each week for up to 4 weeks, with doses adjusted based on your platelet counts. Both groups will receive standard supportive care including blood transfusions and other growth factors as needed. Researchers will monitor your platelet recovery closely, particularly in the first three weeks after your transplant, and continue following your progress over several weeks.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China